599 related articles for article (PubMed ID: 9135089)
1. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.
Lapchak PA; Miller PJ; Collins F; Jiao S
Neuroscience; 1997 May; 78(1):61-72. PubMed ID: 9135089
[TBL] [Abstract][Full Text] [Related]
2. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease.
Araujo DM; Hilt DC
Neuroscience; 1997 Dec; 81(4):1099-110. PubMed ID: 9330371
[TBL] [Abstract][Full Text] [Related]
3. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
Rosenblad C; Martinez-Serrano A; Björklund A
Neuroscience; 1998 Jan; 82(1):129-37. PubMed ID: 9483509
[TBL] [Abstract][Full Text] [Related]
4. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
[TBL] [Abstract][Full Text] [Related]
5. Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection.
Lapchak PA; Beck KD; Araujo DM; Irwin I; Langston JW; Hefti F
Neuroscience; 1993 Apr; 53(3):639-50. PubMed ID: 8098137
[TBL] [Abstract][Full Text] [Related]
6. Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid.
Araujo DM; Hilt DC
Neuroscience; 1998 Jan; 82(1):117-27. PubMed ID: 9483508
[TBL] [Abstract][Full Text] [Related]
7. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
[TBL] [Abstract][Full Text] [Related]
8. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells.
Apostolides C; Sanford E; Hong M; Mendez I
Neuroscience; 1998 Mar; 83(2):363-72. PubMed ID: 9460746
[TBL] [Abstract][Full Text] [Related]
9. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.
Kirik D; Rosenblad C; Björklund A
Eur J Neurosci; 2000 Nov; 12(11):3871-82. PubMed ID: 11069582
[TBL] [Abstract][Full Text] [Related]
10. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Aoi M; Date I; Tomita S; Ohmoto T
Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
[TBL] [Abstract][Full Text] [Related]
11. Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats.
Martin D; Miller G; Cullen T; Fischer N; Dix D; Russell D
Eur J Pharmacol; 1996 Dec; 317(2-3):247-56. PubMed ID: 8997607
[TBL] [Abstract][Full Text] [Related]
12. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats.
Wang Y; Tien LT; Lapchak PA; Hoffer BJ
Cell Tissue Res; 1996 Nov; 286(2):225-33. PubMed ID: 8854891
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of GDNF against 6-OHDA in young and aged rats.
Fox CM; Gash DM; Smoot MK; Cass WA
Brain Res; 2001 Mar; 896(1-2):56-63. PubMed ID: 11277973
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
Lapchak PA; Araujo DM; Hilt DC; Sheng J; Jiao S
Brain Res; 1997 Nov; 777(1-2):153-60. PubMed ID: 9449424
[TBL] [Abstract][Full Text] [Related]
15. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
16. GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine.
Cass WA; Manning MW
J Neurosci; 1999 Feb; 19(4):1416-23. PubMed ID: 9952418
[TBL] [Abstract][Full Text] [Related]
17. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
Bowenkamp KE; Lapchak PA; Hoffer BJ; Miller PJ; Bickford PC
Exp Neurol; 1997 May; 145(1):104-17. PubMed ID: 9184114
[TBL] [Abstract][Full Text] [Related]
18. In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF.
Hoffman AF; van Horne CG; Eken S; Hoffer BJ; Gerhardt GA
Exp Neurol; 1997 Sep; 147(1):130-41. PubMed ID: 9294410
[TBL] [Abstract][Full Text] [Related]
19. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Kirik D; Georgievska B; Rosenblad C; Björklund A
Eur J Neurosci; 2001 Apr; 13(8):1589-99. PubMed ID: 11328352
[TBL] [Abstract][Full Text] [Related]
20. GFR-α1 Expression in Substantia Nigra Increases Bilaterally Following Unilateral Striatal GDNF in Aged Rats and Attenuates Nigral Tyrosine Hydroxylase Loss Following 6-OHDA Nigrostriatal Lesion.
Kasanga EA; Owens CL; Cantu MA; Richard AD; Davis RW; McDivitt LM; Blancher B; Pruett BS; Tan C; Gajewski A; Manfredsson FP; Nejtek VA; Salvatore MF
ACS Chem Neurosci; 2019 Oct; 10(10):4237-4249. PubMed ID: 31538765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
